InMode Ltd. designs, develops, manufactures, and markets minimally-invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radio frequency technologies. The company offers minimally-invasive aesthetic medical products for procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions. InMode Ltd. offers its products directly in the United States, Canada, the United Kingdom, Spain, and India, as well as indirectly through third-party distributors internationally. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was founded in 2008 and is headquartered in Yokneam, Israel.
Industry, Sector and Symbol
Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
Phone972-4909-6313
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$156.36 million
Profitability
Miscellaneous
Employees198
Next Earnings Date5/19/2020 (Estimated)
OptionableNot Optionable
InMode (NASDAQ:INMD) Frequently Asked Questions
What is InMode's stock symbol?
InMode trades on the NASDAQ under the ticker symbol "INMD."
How were InMode's earnings last quarter?
InMode Ltd. (NASDAQ:INMD) issued its quarterly earnings data on Tuesday, February, 18th. The healthcare company reported $0.46 EPS for the quarter, topping the Zacks' consensus estimate of $0.39 by $0.07. The healthcare company earned $47 million during the quarter, compared to the consensus estimate of $42.48 million. InMode had a return on equity of 52.38% and a net margin of 39.10%. The firm's revenue was up 63.3% on a year-over-year basis. During the same period in the prior year, the business earned $0.22 EPS. View InMode's Earnings History.
When is InMode's next earnings date?
What guidance has InMode issued on next quarter's earnings?
InMode issued an update on its FY 2020
Pre-Market earnings guidance on Tuesday, February, 18th. The company provided earnings per share guidance of 1.85-1.93 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.70. The company issued revenue guidance of $190-198 million, compared to the consensus revenue estimate of $190.58 million.
What price target have analysts set for INMD?
4 Wall Street analysts have issued 12-month price objectives for InMode's stock. Their forecasts range from $28.00 to $55.00. On average, they anticipate InMode's share price to reach $45.25 in the next twelve months. This suggests a possible upside of 16.0% from the stock's current price. View Analyst Price Targets for InMode.
What is the consensus analysts' recommendation for InMode?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for InMode in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for InMode.
Has InMode been receiving favorable news coverage?
Press coverage about INMD stock has trended very negative this week, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. InMode earned a media sentiment score of -3.0 on InfoTrie's scale. They also assigned news coverage about the healthcare company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the immediate future. View News Stories for InMode.
Who are some of InMode's key competitors?
Some companies that are related to InMode include GETINGE AB/ADR (GNGBY), LivaNova (LIVN), CONMED (CNMD), Natus Medical (NTUS), AxoGen (AXGN), TransMedics Group (TMDX), Zynex (ZYXI), Cutera (CUTR), Semler Scientific (SMLR), BioLife Solutions (BLFS), Viewray (VRAY), Stereotaxis (STXS), Rockwell Medical (RMTI), Soleno Therapeutics (SLNO) and Fonar (FONR).
What other stocks do shareholders of InMode own?
Who are InMode's key executives?
InMode's management team includes the folowing people:
- Mr. Moshe Mizrahy, Chairman & CEO (Age 66)
- Mr. Yair Malca, Chief Financial Officer (Age 41)
- Dr. Michael Kreindel, CTO & Director (Age 51)
- Mr. Shakil Lakhani, Pres of North America (Age 35)
- Dr. Spero Theodorou, Chief Medical Officer (Age 47)
When did InMode IPO?
(INMD) raised $75 million in an IPO on Thursday, August 8th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. Barclays, UBS Investment Bank and Canaccord Genuity acted as the underwriters for the IPO and Baird was co-manager.
When did the company's lock-up period expire?
InMode's lock-up period expired on Tuesday, February 4th. InMode had issued 5,000,000 shares in its initial public offering on August 8th. The total size of the offering was $70,000,000 based on an initial share price of $14.00. Since the end of the company's lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company have been lifted.
Who are InMode's major shareholders?
InMode's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Penserra Capital Management LLC (0.87%), UBS Group AG (0.34%), Fred Alger Management LLC (0.13%), Alliancebernstein L.P. (0.12%), Ativo Capital Management LLC (0.11%) and Cetera Advisors LLC (0.11%).
Which major investors are selling InMode stock?
INMD stock was sold by a variety of institutional investors in the last quarter, including Penserra Capital Management LLC, Alliancebernstein L.P., Jane Street Group LLC, Emerald Advisers LLC, Raymond James & Associates, Steward Partners Investment Advisory LLC and Optimum Investment Advisors.
Which major investors are buying InMode stock?
INMD stock was acquired by a variety of institutional investors in the last quarter, including UBS Group AG, Cetera Advisors LLC, Oxford Asset Management LLP, Telemus Capital LLC, Acadian Asset Management LLC, Ativo Capital Management LLC, Standard Life Aberdeen plc and ARK Investment Management LLC.
How do I buy shares of InMode?
Shares of INMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is InMode's stock price today?
One share of INMD stock can currently be purchased for approximately $39.00.
How big of a company is InMode?
InMode has a market capitalization of $1.25 billion and generates $156.36 million in revenue each year. The healthcare company earns $22.37 million in net income (profit) each year or $1.60 on an earnings per share basis. InMode employs 198 workers across the globe.View Additional Information About InMode.
What is InMode's official website?
How can I contact InMode?
InMode's mailing address is TAVOR BUILDING SHAAR YOKNEAM POB 533, YOKNEAM L3, 2069200. The healthcare company can be reached via phone at 972-4909-6313 or via email at [email protected]
MarketBeat Community Rating for InMode (NASDAQ INMD)
MarketBeat's community ratings are surveys of what our community members think about InMode and other stocks. Vote "Outperform" if you believe INMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
